ImmuCell Corporation
Find Ratings ReportsIMMUCELL CORP's gross profit margin for the fourth quarter of its fiscal year 2023 has significantly decreased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the subsector when comparing revenue growth, but not when comparing net income growth.
During the same period, stockholders' equity ("net worth") has decreased by 17.73% from the same quarter last year.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q4 FY23 | Q4 FY22 |
---|---|---|
Net Sales ($mil) | 5.1 | 3.91 |
EBITDA ($mil) | 0.0 | -1.03 |
EBIT ($mil) | -1.0 | -1.63 |
Net Income ($mil) | -1.14 | -1.67 |
Balance Sheet | Q4 FY23 | Q4 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 0.0 | 5.79 |
Total Assets ($mil) | 43.81 | 44.86 |
Total Debt ($mil) | 0.0 | 12.48 |
Equity ($mil) | 24.99 | 30.38 |
Profitability | Q4 FY23 | Q4 FY22 |
---|---|---|
Gross Profit Margin | 24.69 | 40.81 |
EBITDA Margin | 0.0 | -26.33 |
Operating Margin | -19.68 | -41.78 |
Sales Turnover | 0.4 | 0.41 |
Return on Assets | -13.18 | -5.55 |
Return on Equity | -23.11 | -8.21 |
Debt | Q4 FY23 | Q4 FY22 |
---|---|---|
Current Ratio | 0.0 | 4.56 |
Debt/Capital | 0.0 | 0.29 |
Interest Expense | 0.0 | 0.09 |
Interest Coverage | 0.0 | -17.57 |
Share Data | Q4 FY23 | Q4 FY22 |
---|---|---|
Shares outstanding (mil) | 7.75 | 7.75 |
Div / share | 0.0 | 0.0 |
EPS | -0.15 | -0.21 |
Book value / share | 3.23 | 3.92 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 7875.0 | 14849.0 |
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 1.60 indicates a significant discount versus the S&P 500 average of 4.68 and a significant discount versus the subsector average of 19.07. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount. After reviewing these and other key valuation criteria, IMMUCELL CORP proves to trade at a discount to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICCC NM | Peers 85.83 | ICCC NA | Peers 38.76 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. ICCC's P/E is negative making this valuation measure meaningless. |
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures. Ratio not available. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
ICCC NA | Peers 18.08 | ICCC NA | Peers 1.16 | |||||||||||||||||||||
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential. Ratio not available. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
ICCC 1.60 | Peers 19.07 | ICCC -141.93 | Peers 12.58 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. ICCC is trading at a significant discount to its peers. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, ICCC is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
ICCC 2.28 | Peers 84.44 | ICCC -5.91 | Peers 42.35 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. ICCC is trading at a significant discount to its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. ICCC significantly trails its peers on the basis of sales growth. |
|||||||||||||||||||||||